| ★ | When Viral Marketing Meets FDA Regulations | JHU Advanced Academic Programs @jhuaap | 35 | Estados Unidos | |
| 5 | RFK Jr. & ‘Secret Science’ Claims: How To Spot The Red Flags Fast | EP#392 | The Proof with Simon Hill @theproofwithsimonhill | — | Estados Unidos | 85 |
| 6 | FDA's Ideological Capture: Drug Company Influence Exposed | | — | Estados Unidos | 85 |
| 20 | Science Headlines Explained: VILPAs, More Beans, & Red Dye No. 3 | 1000 Waking Minutes | Podcast for Healthy Living @1000wakingminutes | — | Estados Unidos | 84 |
| 9 | Science Or Marketing Hype - Dr. Amy Farcas | The Pet Food Science Podcast • by Wisenetix @thepetfoodsciencepodcast | 3.2K | Estados Unidos | 85 |
| 13 | What’s the Problem? Highlighting the Threat of the Illicit Nicotine Product Market | | 858 | Estados Unidos | 85 |
| 2 | GDF2026 - Updates on Nitrosamines/ Nitrosamine Mitigation Strategies for Pharmaceuticals | U.S. Food and Drug Administration @us_fda | 409 | Estados Unidos | 85 |
| 1 | GDF2026 - Recent Trends in Pharmaceutical Freeze-Drying and Control Strategies | U.S. Food and Drug Administration @us_fda | 304 | Estados Unidos | 86 |
| 19 | GDF2026 - Overview of the FDA Product-Specific Guidance (PSG) Program | U.S. Food and Drug Administration @us_fda | 166 | Estados Unidos | 84 |
| 4 | GDF2026 - Regulatory Review Process for Type II Secondary DMFs | U.S. Food and Drug Administration @us_fda | 142 | Estados Unidos | 85 |
| 12 | Public Health Under the New Administration | Network for Public Health Law @networkforpublichealthlaw1992 | 101 | Estados Unidos | 85 |
| 16 | From Science to Cart: How Innovations Move From the Lab to the Marketplace & Shape the Economy | One Minute Finance @oneminutefinance | 99 | Reino Unido | 85 |
| 14 | GDF2026 - Complex Drug Products – Quality Considerations for Generic Oligonucleotides | U.S. Food and Drug Administration @us_fda | 86 | Estados Unidos | 85 |
| 15 | Supplements, Safety, and the Truth | Speaking of Pets Podcast @speakingofpets | 73 | Estados Unidos | 85 |
| 18 | GDF2026 - Addressing Patent and Exclusivity Requirements – Regulatory Reminders | U.S. Food and Drug Administration @us_fda | 66 | Estados Unidos | 84 |
| 8 | GDF2026 - Product-Specific Guidances (PSGs) in Action – Key Lessons and Common Questions | U.S. Food and Drug Administration @us_fda | 58 | Estados Unidos | 85 |
| 11 | GDF2026 - Decoding PSGs for Complex Non-Oral Generics | U.S. Food and Drug Administration @us_fda | 49 | Estados Unidos | 85 |
| 3 | GDF2026 - Using FDA’s Inactive Ingredient Database (IID): Best Practices and Considerations | U.S. Food and Drug Administration @us_fda | 47 | Estados Unidos | 85 |
| 10 | Beyond the Lab Bench The Micro Nutrition Startup's Hidden Playbook | Inspiring Entrepreneur Tales @inspiringentrepreneurtales | 38 | Estados Unidos | 85 |
| 7 | GDF2026 - Controlled Correspondences: Minimizing Rejections, Maximizing Results | U.S. Food and Drug Administration @us_fda | 37 | Estados Unidos | 85 |
| 17 | Nerd Out with Nutrition - Vitamins and Supplements - June 2026 | Shrewsbury Media Connection @shrewsburymedia | 21 | — | 84 |